Pharmacokinetic studies of ambenonium chloride in patients with myasthenia gravis.

Abstract	Serum levels of ambenonium chloride (AC) were monitored in 4 myasthenic patients. This determination revealed important intraindividual variations (up to 10-fold) over a period of 24 h. Levels varied considerably between different patients (maximum serum concentration of ambenonium chloride ranged from 0.129 to 0.812 micrograms/ml) and no correlation between the daily dose and the AUC was found. These characteristic properties of ambenonium chloride could explain the erratic pattern of bioavailability observed as well as the difficulty in controlling the disease in some patients.
Authors	C Tharasse-Bloch, C Chabenat, P Boucly, J Marchand, D Elkharrat, C Boucly-Goester, P Gajdos
Journal	European journal of drug metabolism and pharmacokinetics (Eur J Drug Metab Pharmacokinet) 1991 Oct-Dec Vol. 16 Issue 4 Pg. 299-303 ISSN: 0378-7966 [Print] France
PMID	1823874 (Publication Type: Journal Article)
Chemical References	Ambenonium Chloride
Topics	Administration, Oral Adult Aged Aged, 80 and over Ambenonium Chloride (blood, pharmacokinetics) Biological Availability Female Humans Male Myasthenia Gravis (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!